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B-cell Complement Dependent Cytotoxic Crossmatch Positivity is 
an Independent Risk Factor for Long-term Renal Allograft Survival
The clinical significance of positive B-cell complement-dependent cytotoxicity 
crossmatching (B-CDC) in renal transplant recipients remains unclear. We reviewed 20 
recipients with isolated B-CDC positivity at the time of transplantation. We compared the 
clinical characteristics, acute rejection and long-term graft survival between positive and 
negative B-CDC patients (n = 602). The number of retransplant recipients and positivity for 
T- and B-flowcytometric crossmatch was greater in positive B-CDC patients than in 
negative B-CDC patients. The overall acute rejection rate of positive B-CDC patients was 
significantly higher (P < 0.001), and Banff grade II or III cellular rejection was more 
frequently observed in positive B-CDC patients (P = 0.037). Compared with negative 
B-CDC patients, acute cellular rejection as a cause of graft loss was more prevalent  
(P = 0.020) and rescue rejection therapy was more frequently needed in positive B-CDC 
patients (P = 0.007). The allograft survival rate of positive B-CDC patients was significantly 
lower than that of negative B-CDC patients (P < 0.001), and B-CDC positivity 
independently increased the risk of allograft failure 2.31-fold (95% CI 1.15–4.67;  
P = 0.019) according to multivariate analysis. In conclusion, isolated B-CDC positivity is an 
independent long-term prognostic factor for allograft survival.
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INTRODUCTION
The complement-dependent cytotoxicity crossmatching test 
(CDC) is a widely used tissue-typing technique for detecting 
donor-specific anti-human leukocyte antigen (HLA) antibodies 
in renal transplantation. Because the CDC utilizes donor T- and 
B-cells, its interpretation is based on positivity for each cell type. 
Positive crossmatching on donor T-lymphocytes is recognized 
as the presence of anti-HLA class I antibodies and is a signifi-
cant barrier to renal transplantation (1). In contrast, the value of 
a positive CDC for B lymphocytes (B-CDC) is unclear because 
B-cells do not express a uniform HLA antigen.
  B lymphocytes express HLA class II molecules and constitu-
tively express HLA class I molecules at a higher density than T-
cells. Therefore, B-CDC positivity may reflect anti-HLA class II 
activity or weak anti-HLA class I activity. In addition, non-HLA 
antibodies and autoantibodies also result in positivity for B-CDC 
(2, 3). This heterogeneity of B-CDC contributes to the debates 
surrounding the effects of B-CDC positivity on renal transplan-
tation with a concomitant negative T-CDC. Hyperacute vascu-
lar rejection in B-CDC positive recipients has been reported (4, 
5), but some investigators have found that it has no influence 
on transplant outcome (6-12). Apart from these immediate an-
ti-donor antibody responses, there are few reports indicating 
that B-CDC positivity influences long-term allograft survival or 
that renal transplant recipients with B-CDC positivity experi-
ence more adverse immunologic events.
  Therefore, the aim of this study was to determine whether B-
CDC positivity affects long-term renal allograft survival and 
whether positive B-CDC recipients experience more adverse 
immunologic events. We also sought to determine whether B-
CDC positivity is independently predictive of renal allograft sur-
vival.
MATERIALS AND METHODS
Patients
A retrospective review was performed of 735 renal transplant 
recipients from January 1995 to August 2008 at Seoul St. Mary’s 
Hospital Transplantation Center. Of these patients, 113 cases 
were excluded because of T-CDC positivity (n = 4), unavailable 
flowcytometric crossmatching test (FCXM) results (n = 85) or 
incomplete medical records (n = 24). Therefore, 20 renal trans-
plant recipients with a positive B-CDC result and 602 recipients 
with a negative B-CDC result were enrolled in this study. Clini-
cal data including demographics, pretransplant immunologic Hwang HS, et al.  •  Renal Transplantation across Positive B-cell Cytotoxic Crossmatch
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status and biopsy-proven acute rejection were collected. Allograft 
loss was defined as return to maintenance dialysis, transplant 
nephrectomy or patient death with or without a functioning graft.
 
Complement-dependent cytotoxicity test
Donor T- and B-cells were isolated using CD19 monoclonal an-
tibody attached to beads. One microliter of donor cell suspen-
sion (2 × 10
6 cells/mL) was incubated with 1 μL of recipient se-
rum for 30 min at room temperature. Anti-human globulin 1 μL 
was added and incubated for 30 min at 37°C. After washing the 
cells, rabbit complement was added and incubated for 60 min 
at room temperature. The cells were stained with acridine or-
ange and ethidium bromide, and observed for cytotoxicity us-
ing an immunofluorescent microscope. CDC results for T- and 
B-cells were considered positive when cell death exceeded that 
of the negative control well by 20%.
Flowcytometric crossmatch test
For the assay, 2 × 10
5 donor lymphocytes were added to 50 μL 
of patient serum and then incubated for 30 min at room tem-
perature. Fluorescein isothiocyanate-labeled anti-human IgG 
(DAKO, Tokyo, Japan) and phycoerythrin-labeled CD19 or CD3 
(DAKO) were added and incubated for 30 min. After washing 
the cells, a Coulter EPICS XL (Beckman Coulter, San Diego, CA, 
USA) was used for analysis. A positive FCXM was defined as a 
displacement of the mean channel fluorescence (MCF) by 
more than 10 channels relative to a negative control and donor 
autologous control. We also confirmed positive cases as having 
a relative median fluorescence (test MCF ÷ [recipient autolo-
gous MCF + donor autologous MCF + healthy autologous MCF] / 
3) ≥ 1.5 and a test MCF greater than that of the negative MCF + 
3SDs.
Detection of donor-specific antibody
Panel-reactive antibody (PRA) tests and antibody monitoring 
system (AMS; GTI Inc., Waukesha, WI, USA) were used to detect 
the presence of donor-specific anti-HLA antibodies (DSA) in re-
cipients. PRA was determined by enzyme-linked immunoab-
sorbent assays (ELISA) (LAT, One Lambda Inc., CA, USA). Posi-
tive sera were defined as those with values ≥ 20% of the positive 
control. When anti-HLA antibodies were positive by ELISA-
PRA, the HLA specificity was confirmed by PRA identification. 
If the detected anti-HLA antibodies corresponded with relevant 
donor HLA antigen, we confirmed the detected anti-HLA anti-
bodies as DSA. AMS is a solid-phase ELISA crossmatch test for 
detecting IgG antibody to the donor-specific solubilized HLA 
class I and class II antigens. We previously reported that AMS is 
useful as a supportive crossmatch test or as a monitoring test for 
detecting class I or II donor-specific anti-HLA antibodies (13, 
14). The results of PRA screening were known in 233 (37.5%) pa-
tients (5 in positive B-CDC and 228 in negative B-CDC patients, 
and DSA detection was available in 226 (36.3%) patients (4 in 
positive B-CDC and 222 in negative B-CDC patients).
 
Immunosuppressive regimen
The patients received initial immunosuppression with a calci-
neurin inhibitor in combination with mycophenolate mofetil 
and prednisolone after transplantation. If recipients were high-
ly sensitized, renal transplantations were performed after a de-
sensitization protocol involving plasmapheresis and intravenous 
immunoglobulin (15). Cyclosporine was used for 442 patients, 
and the others were treated with tacrolimus. The initial dose of 
cyclosporine A was 10 mg/kg per day by the oral route; the tar-
get trough levels were 200-400 ng/mL during the first 4 weeks 
and 100-200 ng/mL thereafter. The initial dose of FK506 was 0.16 
mg/kg per day by the oral route, and target trough levels were 
8-15 ng/mL during the first 3 months and 3-8 ng/mL thereafter. 
Methylprednisolone (1 g/day) was administered by intravenous 
infusion on the day of transplantation, and the dose was then 
tapered to prednisone at 30 mg/day on the fourth day after trans-
plantation. Mycophenolate mofetil (1.5 g/day) was initially used 
for 338 recipients, and the dose was modified to minimize ad-
verse effects such as diarrhea or leukopenia.
Pathological diagnosis and treatment of acute rejection
Acute rejection was diagnosed by core needle biopsy. We re-
viewed the pathological evidence of acute rejection and graded 
it according to the Banff 97 working classification of renal al-
lograft pathology (16). Hyperacute or accelerated rejection was 
considered as acute antibody-mediated rejection (AMR) based 
on pathological findings. Acute cellular rejection was treated 
with 3-4 daily boluses of intravenous methylprednisolone (500 
mg/day), followed by a 5- to 7-day oral steroid taper. Anti-thy-
mocyte globulin (ATG) or muromonab-CD3 (OKT3) was used 
as a rescue regimen when methylprednisolone was not effec-
tive against acute rejection.
Ethics statement
The study was approved by the institutional review board of 
Seoul St. Mary’s Hospital (KC10RISI0081). The board granted 
us an exemption for our retrospective study; additional patient 
informed consent was not required.
Statistical analysis
Descriptive statistical values are presented as the mean ± SD or 
median with range. Continuous variables with a normal distri-
bution were analyzed using Student’s t-test, and the chi-square 
test was used for analysis of categorical variables. Graft survival 
was analyzed using the Kaplan-Meier method with a log-rank 
test. A univariate test followed by a multivariate Cox-regression 
test was used to determine independent predictors of graft sur-
vival. Variables that showed a trend toward significance (P < 0.1) Hwang HS, et al.  •  Renal Transplantation across Positive B-cell Cytotoxic Crossmatch
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were included in the multivariate models. A P value of < 0.05 was 
considered statistically significant. Statistical analysis was per-
formed using SPSS version 16.0 software.
RESULTS
Baseline characteristics and pretransplant immunological 
status in positive and negative B-CDC patients
The age, sex and follow-up years were not different between pos-
itive and negative B-CDC patients (Table 1). There were many 
retransplant recipients and living unrelated donors in positive 
B-CDC patients. The incidence of positivity for T- (15.0% vs 3.8%) 
and B-FCXM (65.0% vs 8.8%) was higher in positive B-CDC pa-
tients than in negative B-CDC patients (Table 2). The percent-
age panel reactivity against HLA class I (%PRA I) and positivity 
for DSA class I were not significantly different. However, %PRA 
II values (65.0% vs 8.8%) and positive rates for DSA class II (50.0% 
vs 2.3%) were greater in positive B-CDC patients than in nega-
tive B-CDC patients. The pretransplant desensitization was more 
frequently performed (25.0% vs 2.5%) in positive B-CDC pati-
ents. Of these, three underwent desensitization because of a 
positive T-FCXM, one underwent desensitization because of 
high panel reactivity and one underwent desensitization be-
cause of retransplantation with a rejection history. In negative 
B-CDC patients, 15 patients underwent desensitization; the rea-
sons were T-FCXM positivity (n = 13), high %PRA I and II (n = 1), 
and positive historic T-FCXM and current positive PRA I (n = 1).
Comparison of acute rejection between positive and 
negative B-CDC patients
Of the positive B-CDC patients, 15 episodes of acute rejection 
developed in 12 patients. The overall incidence of acute rejec-
tion was significantly higher in positive B-CDC patients than in 
negative B-CDC patients (14/20 vs 146/602; P < 0.001) (Table 3). 
Compared with negative B-CDC patients, peak serum creati-
nine level during rejection episodes was significantly higher in 
positive B-CDC patients (4.9 vs 3.3 mg/dL; P = 0.019). Acute re-
jections requiring ATG or OKT 3 rescue therapy were observed 
more frequently in positive B-CDC patients (35.7% vs 10.9%; P = 
0.007). We compared rejection type between positive and nega-
tive B-CDC patients. No significant differences were observed 
in acute AMR (14.3% vs 4.0%; P = 0.138). However, grade II or III 
acute cellular rejection was significantly greater in positive B-
CDC patients than in negative B-CDC patients (35.7% vs 14.5%; 
P = 0.037). The rate of grade I acute cellular rejection for positive 
B-CDC patients was lower than that for negative B-CDC patients 
(50.0% vs 81.5%; P = 0.005).
Comparison of graft survival and causes of allograft loss 
between positive and negative B-CDC patients
The allograft survival curve of positive B-CDC patients is illus-
trated in Fig. 1. The 5- and 10-yr graft survival rates were 70.0% 
and 43.8%, which were significantly lower than those of nega-
tive B-CDC patients (88.2% and 75.1%; P < 0.001). When patient 
death with a functioning graft was censored, positive B-CDC 
patients also showed a poorer graft survival rate than negative 
B-CDC patients (P = 0.005).
  We compared the causes of allograft loss between positive 
and negative B-CDC patients (Table 4). The five patients (55.6%) 
Table 1. Basal patient characteristics and pre-transplant immunologic status
Positive B-CDC  
(n = 20)
Negative B-CDC  
(n = 602) P
Age (yr) 49.5 (33-68)     46 (17-77) 0.058
Male (%)   8 (40.0) 356 (59.1) 0.938
Follow-up (yr) 5.2 ± 4.2 5.1 ± 3.7 0.852
Retransplantation (%)   5 (25.0)  45 (7.5)  0.005
Deceased donor (%)   3 (15.0)    61 (10.1)  0.711
Delayed graft function (%)   2 (10.0) 29 (4.8) 0.263
LURD (%) 15 (75.0) 243 (40.4) 0.002
Data expressed as median (range), means ± SD or number (percent). B-CDC, B-cell 
complement dependent cytotoxicity test; LURD, living unrelated donor.
Table 2. Pre-transplant immunologic status and immunosuppressants
Positive B-CDC  
(n = 20)
Negative B-CDC  
(n = 602) P
Immunologic status
   Positive T-FCXM (%)
   Positive B-FCXM (%)
   % PRA I*
   % PRA II*
   Positive DSA I (%)
†
   Positive DSA II (%)
†
   HLA- mismatch number
 
  3 (15.0) 
13 (65.0) 
  5.6 ± 16.9
32.0 ± 43.8
  1 (25.0)
  2 (50.0)
3.0 ± 1.5
 
23 (3.8) 
53 (8.8) 
4.0 ± 8.9
  4.1 ± 17.4
  9 (4.1)
  5 (2.3)
3.3 ± 1.4
 
0.046
< 0.001
0.673
0.002
0.167
0.005
0.768
Immunosuppression
   FK506 (%)
   MMF (%)
   Pretransplant desensitization (%)
 
  6 (30.0)
  7 (35.0)
  5 (25.0)
 
174 (28.9)
331 (55.0)
15 (2.5)
 
0.915
0.078
< 0.001
Data expressed as means ± SD or number (percent). *The results of PRA screening 
were known in 233 (37.5%) of the 622 patients: 5 in the positive B-CDC patients and 
228 in the negative B-CDC patients; 
†The results of DSA were known in 226 (36.3%) 
of the 622 patients: 4 in the positive B-CDC patients and 222 in the negative B-CDC 
patients. B-CDC, B-cell complement dependent cytotoxicity test; % PRA, percent panel 
reactive antibody; DSA, donor-specific antibody; FCXM, flowcytometric crossmatch 
test. 
Table 3. Comparison of acute rejection episodes between positive and negative B- 
CDC patients
Positive  
B-CDC  
(n = 14)
Negative 
B-CDC 
(n = 173)
P
Peak Cr (mg/dL)* 4.9 ± 2.7 3.3 ± 2.4 0.019
ATG or OKT3 rescue (%) 5 (35.7)   19 (10.9) 0.007
Rejection type
   Acute antibody-mediated rejection (%)
   Acute cellular rejection grade I (%)
   Acute cellular rejection grade II or III (%)
 
2 (14.3)
7 (50.0)
5 (35.7)
 
  7 (4.0)
141 (81.5)
  25 (14.5)
 
0.138
0.005
0.037
*Peak serum creatinine level during rejection episodes. B-CDC, B-cell complement 
dependent cytotoxicity test; Cr, serum creatinine; ATG, anti-thymocyte globulin; OKT3, 
muromonab-CD3.Hwang HS, et al.  •  Renal Transplantation across Positive B-cell Cytotoxic Crossmatch
http://jkms.org   531 DOI: 10.3346/jkms.2011.26.4.528
with B-CDC positivity experienced graft loss caused by acute 
cellular rejection, the incidence of which was significantly great-
er compared with negative B-CDC patients (17.9%, P = 0.020). 
Acute AMR caused allograft loss in two (22.2%) positive B-CDC 
patients and in five (6.0%) negative B-CDC patients (P = 0.136). 
The incidence of chronic allograft nephropathy and patient 
death, as causes of graft loss were not significantly different be-
tween positive and negative B-CDC patients.
B-CDC positivity as an independent prognostic factor for 
allograft survival
To identify prognostic factors associated with allograft survival, 
all of the clinical and immunologic parameters were analyzed 
by univariate and multivariate models (Table 5). Univariate anal-
ysis revealed that B-CDC positivity, HLA mismatch number and 
the number of acute rejection episodes were significant predic-
tors of graft survival. The other variables that showed a trend to-
ward significance (P < 0.1) were deceased donor and delayed 
graft function.
  In the multivariate analysis, the independent predictors of 
allograft survival were B-CDC positivity, HLA mismatch num-
ber and number of acute rejection episodes. Deceased donor 
and delayed graft function were not significant in predicting 
graft survival. The relative risk was 2.31 for B-CDC positivity (95% 
confidence interval [CI], 1.15-4.67; P = 0.019), 1.21 for one HLA 
mismatch (95% CI, 1.04-1.41; P = 0.015) and 2.67 for one acute 
rejection episode (95% CI, 2.14-3.31; P < 0.001).
DISCUSSION
This study demonstrated that positive B-CDC patients showed 
a higher acute rejection rate and that Banff grade II or III rejec-
tion was more prevalent among positive B-CDC patients. Com-
pared with negative B-CDC patients, rescue rejection therapy 
was needed more often for positive B-CDC patients, and acute 
cellular rejection resulted in graft loss more frequently in posi-
tive B-CDC patients. Furthermore, B-CDC positive patients had 
a lower allograft survival rate than negative B-CDC patients. 
These findings suggest that isolated B-CDC positivity is associ-
ated with poor renal allograft outcome.
  Comparison of pretransplant immunologic status between 
Table 4. Causes of allograft loss in positive and negative B-CDC patients
Positive B-CDC 
(n = 9)
Negative B-CDC 
(n = 84) P
Chronic allograft nephroapthy (%) 1 (11.1) 30 (35.7) 0.263
Patient death (%) 1 (11.1) 21 (25.0) 0.451
Acute cellular rejection (%) 5 (55.6) 15 (17.9) 0.020
Acute antibody-mediated rejection (%) 2 (22.2) 5 (6.0) 0.136
Others (%) 0 13 (15.5) 0.351
B-CDC, B-cell complement dependent cytotoxicity test.
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Fig. 1. Comparison of allograft survival between positive and negative B-CDC patients. 
Note that the survival rates for positive B-CDC patients was significantly lower than 
negative B-CDC patients (P < 0.001).
Negative B-CDC
Positive B-CDC
  602  487  433  376  339  287  246  200  156  117  72 Negative 
B-CDC
  20  14  12  11  11  11  8  6  6  4  4 Positive 
B-CDC
Table 5. Univariate and multivariate analysis for prognostic factors influencing allograft survival rates
Univariate analysis Multivariate analysis
Relative risk (95% CI) P Relative risk (95% CI ) P
Age (per one year) 1.01 (0.99-1.03) 0.384 -
Male (vs female) 1.07 (0.71-1.61) 0.760 -
Retransplantation 1.08 (0.52-2.24) 0.827 -
Deceased donor 1.70 (0.96-3.01) 0.069 1.26 (0.64-2.49) 0.500
Positive B-CDC 3.22 (1.62-6.42) 0.001 2.31 (1.15-4.67) 0.019
Positive T-FCXM 1.18 (0.84-3.92) 0.132 -
Positive B-FCXM 1.49 (0.87-2.57) 0.146 -
HLA mismatch number (per one mismatch ) 1.25 (1.02-1.54) 0.031 1.21 (1.04-1.41) 0.015
DGF 1.88 (0.91-3.88) 0.089 1.03 (0.44-2.38) 0.948
Use of FK506 1.26 (0.79-2.02) 0.330 -
Use of MMF 0.90 (0.55-1.47) 0.671 -
Number of acute rejection (per one episode) 2.75 (2.23-3.37) < 0.001 2.67 (2.14-3.31) < 0.001
CI, confidence interval; B-CDC, B-cell complement dependent cytotoxicity test; FCXM, flowcytometric crossmatch test; DGF, delayed graft function; MMF, mycophenolate mofetil.Hwang HS, et al.  •  Renal Transplantation across Positive B-cell Cytotoxic Crossmatch
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positive and negative B-CDC patients revealed that positivity 
for T-FCXM was higher in positive B-CDC recipients (15.0% vs 
3.8%). This finding suggests that B-CDC positivity increases the 
risk of acute AMR via the anti-HLA class I antibody (17, 18). Fur-
thermore, 11 (55%) of the positive B-CDC patients were positive 
for B-FCXM but negative for T-FCXM, and the %PRA II value 
and DSA class II was higher in positive B-CDC patients. These 
findings suggest that B-CDC positivity is associated with sensi-
tization for donor-specific anti-HLA class II antibody as well as 
anti-HLA class I antibody.
  It is still controversial whether desensitization is needed in 
isolated positive B-CDC patients. In our center, desensitization 
is indicated in positive B-CDC recipients with high immunolog-
ic risk. However, of the patients who did not receive desensiti-
zation, two recipients experienced acute AMR, resulting in al-
lograft loss. Interestingly, these patients were also positive for 
B-FCXM. This finding suggests that DSA against HLA class II 
may cause acute AMR, which is supported by previous reports 
that anti-HLA class II DSA is associated with the hyperacute re-
jection (19, 20). Therefore, pretransplant desensitization is sug-
gested for patients with simultaneous positivity for B-CDC and 
B-FCXM.
  Compared with negative B-CDC patients, peak serum creati-
nine level during rejection episodes and the prevalence of vas-
cular rejection (Banff grades II or III) were significantly greater 
in positive B-CDC patients. Furthermore, acute rejections re-
quiring rescue therapy and graft loss due to acute cellular rejec-
tion were more frequently observed in positive B-CDC patients. 
These findings suggest that acute rejections in B-CDC positive 
patients are more serious than those in negative B-CDC patients 
and that conventional anti-rejection treatment is not enough to 
overcome acute rejection in positive B-CDC patients. Otherwise, 
acute cellular rejection in positive B-CDC patients may be com-
bined with antibody-mediated injury. Because humoral immu-
nity is associated with vascular rejection, it may result in more 
adverse outcome of graft rejection in positive B-CDC patients 
(21-23).
  Our study revealed that the incidence of acute AMR and al-
lograft loss due to acute AMR were not significantly different 
between positive and negative B-CDC patients. However, the 5- 
and 10-yr graft survival rates of positive B-CDC patients were 
lower than those of negative B-CDC patients (70.0% vs 88.2% 
and 43.8% vs 75.1%). In the multivariate analysis, B-CDC posi-
tivity was as important as one acute rejection episode as an in-
dependent predictor of allograft survival (2.31 risk for B-CDC 
positivity vs 2.67 risk for one acute rejection episode). These find-
ings suggest that B-CDC positivity contributes substantially to 
long-term kidney-transplant failure, although pretransplant 
desensitization in positive B-CDC patients can produce favour-
able short-term results.
  The results of our study show the importance of B-CDC posi-
tivity in renal transplantation, but there are some limitations. 
First, the present study is observational, and immunosuppres-
sive treatment was not consistent for each patient. Second, the 
PRA and AMS assay were restrictively allowed, because a solid-
phase detection method was not available at the earlier time of 
study. Third, the lymphocytotoxic crossmatch test lacks speci-
ficity for HLA antigen and sensitivity for noncomplement fixing 
antibodies. Therefore, more sensitive ELISA or Luminex tech-
niques for detecting DSA are needed considering a recent re-
port showing that DSA is important for allograft survival in B-
cell crossmatch-positive patients (24).
  In conclusion, patients with B-CDC positivity are an immu-
nologically high risk group for renal transplantation, and B-CDC 
positivity has an independent role in long-term renal allograft 
survival. Therefore, B-CDC positivity should be cautiously in-
terpreted before renal transplantation.
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The clinical significance of positive B-cell complement-dependent cytotoxicity crossmatching (B-CDC) in renal transplant recipients 
remains unclear. We compared the clinical characteristics, acute rejection and long-term graft survival between positive and 
negative B-CDC patients. The positivity for T- and B-flowcytometric crossmatch was greater in positive B-CDC patients than in the 
negative. The incidence of acute rejection episodes was significantly greater in positive B-CDC patients. Also, the allograft survival 
rate of positive B-CDC patients was significantly lower than that of the negative. As a whole, B-CDC positivity increased the risk of 
allograft failure 2.31-fold. 